Use of pembrolizumab as first-line treatment in patients with non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥ 50 % was approved in Japan 5 years ago. We investigated the long-term efficacy and safety of this treatment in a real-world setting. This multicenter observational study enrolled 95 consecutive cases of histologically diagnosed advanced or recurrent NSCLC with a PD-L1 TPS score ≥ 50 %, who received pembrolizumab as first-line treatment between February 2017 and December 2018. Clinical data were collected from electronic medical records. PD-L1 TPS scores were assessed immunohistochemically, using the 22C3 antibody. The median follow-up period was 71.1 months. The median progression-free survival (PFS) was 6.9 months (95 % confidence interval [CI]; 4.7-9.1 months), and the 2-, 3-, and 5-year PFS rates were 24.9 %, 19.3 %, and 14.2 %, respectively. The median overall survival (OS) was 19.1 months (95 %CI; 13.3-24.9 months). The 2-, 3-, and 5-year OS rates were 42.7 %, 33.9 %, and 24.8 %, respectively. On multivariate analysis, histology (squamous vs. non-squamous cell carcinoma; hazard ratio [HR] 2.23, 95 %CI 1.40-3.89, p = 0.001) and number of metastatic sites (< 3 vs. ≥ 3; HR 4.65 95 %CI 2.51-8.62, p < 0.001) independently affected long-term survival. Immune-related adverse events occurred in 43 cases (45.3 %; 20 [21.0 %] Grade ≥ 3). The real-world 5-year survival rate of NSCLC cases with PD-L1 ≥ 50 % treated with first-line pembrolizumab was comparable to that in a clinical trial. Histological type and number of metastatic sites influenced long-term and 5-year survival.
Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer therapy. Trastuzumab deruxtecan (T‐DXd), a human epidermal growth factor receptor 2 (HER2)‐directed ADC, has demonstrated clinical efficacy in HER2‐positive gastric and breast cancers, as well as in HER2‐mutant non‐small cell lung cancer. However, the development of acquired resistance limits their long‐term efficacy. To elucidate the resistance mechanism, we established T‐DXd‐resistant cell lines derived from HER2‐amplified gastric xenografts (N87 acquired resistance [AR]) and leptomeningeal carcinomatosis (Calu‐3 AR) lung cancer cells. N87 AR cells exhibited cross‐resistance to T‐DXd, payload DXd, and topoisomerase I inhibitor SN‐38 despite preserved HER2 expression and intact drug internalization. As payload resistance‐related molecules, ATP‐binding cassette (ABC) transporter ABCG2 and ABCB1 were markedly upregulated in N87 AR and Calu‐3 cells, respectively. Inhibition of ABCG2 and ABCB1 in N87 AR and Calu‐3 cells, respectively, through siRNA‐mediated knockdown restored T‐DXd sensitivity in both models. As a strategy to overcome resistance, pharmacological inhibitors of ABCG2 and ABCB1 restored the T‐DXd sensitivity of N87 AR and Calu‐3 cells, respectively. Moreover, BB‐1701, a novel HER2‐ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in vitro and in vivo. These findings indicate that ABC transporter‐mediated drug efflux is an important mechanism underlying T‐DXd resistance in HER2‐positive gastric and lung cancer models. Furthermore, our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effective strategies for overcoming T‐DXd resistance in HER2‐positive gastric and lung cancers.
Curative surgery followed by adjuvant osimertinib according to pathological stage (pStage) is standard for resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Nevertheless, recurrence remains a concern even in Stage IA, for which adjuvant osimertinib is not indicated. We evaluated the utility of circulating tumor DNA (ctDNA) to predict recurrence in patients with resected pStage I-III EGFR-mutated NSCLC and examined prognostic value of preoperative biomarkers and pathological features. Between January 2017 and May 2020, 382 patients with lung tumors underwent surgery at Kanazawa University Hospital, including 88 with NSCLC harboring common EGFR mutations. Preoperative ctDNA was analyzed using droplet digital PCR, targeting EGFR mutations. Patients were followed for up to 6.4 years, and disease-free survival (DFS) and overall survival (OS) were evaluated. Preoperative ctDNA positivity was detected in 26.1 % and venous invasion in 39.8 %. ctDNA-positive patients had lower 60-month DFS (54.1 % vs. 84.1 %; HR = 3.25; 95 % CI, 1.13-9.21; p = 0.028) and 60-month OS (65.1 % vs. 95.9 %; HR = 6.10; 95 % CI, 1.11-33.46; p = 0.037). Venous invasion was independently associated with poorer DFS (HR = 8.73; 95 % CI, 1.81-41.93; p = 0.0068). In combined analyses, no recurrences occurred in the double-negative, whereas the double-positive had a lower 60-month DFS than the single-positive (HR = 3.61; 95 % CI, 1.19-10.93; p = 0.023). Preoperative ctDNA detection and pathological venous invasion provide complementary prognostic information, and venous invasion is an independent predictor of recurrence risk in EGFR-mutated NSCLC. Combined assessment may refine postoperative risk stratification and inform perioperative management.
Amivantamab is a bispecific antibody against epidermal growth factor receptor (EGFR) and MET that has been approved for nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations and common EGFR mutations, such as exon 19 deletion and L858R. MET has attracted attention as a therapeutic target for lung cancer; however, its role in EGFR binding and amivantamab‐induced antibody‐dependent cellular toxicity (ADCC) remains unclear. We used high‐speed atomic force microscopy (HS‐AFM) to observe the real‐time binding of amivantamab to the EGFR‐extracellular domain (ECD) and MET‐ECD and visualized the binding of amivantamab to the EGFR domain 3 and MET Sema domain. Furthermore, we observed the trimer comprising amivantamab bound to EGFR and MET. Western blot analysis of the gel filtration fractions revealed that the MET‐ECD enhanced the binding of amivantamab to the EGFR‐ECD, which promoted trimer formation. Moreover, amivantamab‐induced mononuclear cell‐mediated ADCC in NSCLC cells with common EGFR mutations. ADCC activity was positively correlated with EGFR expression in tumor cells. Studies using MET‐knockout NSCLC cells revealed that MET enhanced ADCC activity with low concentrations of amivantamab. Thus, MET augments amivantamab binding to EGFR and augments ADCC activity at low amivantamab concentrations. These results indicate that binding to MET contributes to the increased efficacy of amivantamab in NSCLC with common EGFR mutations.
16 May 2026 in International Journal of Lung Cancer
Summary: Background: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome is a rare inflammatory disease that manifests as a paraneoplastic manifestation of malignant tumors. Although its association with non-small cell lung cancer (NSCLC) is rare, vascular endothelial growth factor (VEGF)-A has been suggested to be involved in the pathogenesis. Cases with pleural and pericardial effusions are even rarer, and differentiation from metastasis of malignant tumors is important. Case presentation: A 51-year-old Asian man presented with fever, bilateral edema, tenosynovitis, pleural effusion, and pericardial effusion. Cytology of both effusions was negative for malignant cells, but mediastinal lymph node biopsy revealed adenocarcinoma. He was diagnosed with RS3PE syndrome associated with NSCLC. Oral prednisolone and chemoradiotherapy improved the edema and effusions. Serum VEGF‑A measured after clinical improvement was lower than that observed at recurrence. After curative resection of synchronous double primary lung cancers (adenocarcinoma and squamous cell carcinoma) and adjuvant chemotherapy, central nervous system metastases developed 10 months later. This recurrence was accompanied by elevated serum and cerebrospinal fluid VEGF‑A levels and recurrence of RS3PE symptoms. Immunohistochemical analysis showed strong VEGF‑A expression in pretreatment tumor tissue, which decreased after treatment. Discussion and conclusion: This case suggests that VEGF‑A may have contributed to paraneoplastic RS3PE syndrome in NSCLC. The association among the available VEGF‑A measurements, RS3PE activity, and cancer progression suggests that VEGF‑A may serve as a potential disease activity biomarker in selected patients. This case also highlights the importance of recognizing RS3PE syndrome as a paraneoplastic process and carefully evaluating pleuropericardial effusions and thrombotic complications in complex oncological patients.